| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
|
| | RO 0437626 Basic information |
| Product Name: | RO 0437626 | | Synonyms: | RO 0437626;N-[(1R)-2-[[(1S,2R,3S)-1-(Cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]amino]-2-oxo-1-(4-thiazolylmethyl)ethyl]-1H-benzimidazole-2-carboxamide;1H-Benzimidazole-2-carboxamide, N-[(1R)-2-[[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]amino]-2-oxo-1-(4-thiazolylmethyl)ethyl]- | | CAS: | 134362-79-1 | | MF: | C27H35N5O4S | | MW: | 525.66 | | EINECS: | | | Product Categories: | | | Mol File: | 134362-79-1.mol |  |
| | RO 0437626 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | | form | Powder |
| | RO 0437626 Usage And Synthesis |
| Uses | Ro 0437626 is a P2X1 purinergic receptor antagonist. | | Biological Activity | Selective P2X 1 purinergic receptor antagonist (IC 50 = 3 μ M) that displays > 30-fold selectivity over P2X 2 , P2X 3 and P2X 2/3 receptors (IC 50 > 100 μ M). | | in vivo | Ro 0437626 (1 and 10 μmol/kg; i.v.) causes a reduction in postinfusion isovolumetric contractions[3]. | Animal Model: | Female rat (urethane-anaesthetized)[3] | | Dosage: | 1 and 10 μmol/kg | | Administration: | I.v. | | Result: | Caused a reduction in postinfusion isovolumetric contractions.
|
|
| | RO 0437626 Preparation Products And Raw materials |
|